Document:

Exhibit 10.9

                              CONSULTANCY AGREEMENT

      THIS CONSULTANCY AGREEMENT (this "Agreement") is made as of this 19th day
of January, 2005, by and between Advaxis, Inc, a Colorado corporation, having a
principal place of business at 212 Carnegie Center, Princeton, NJ ("Company"),
and LVEP Management, LLC with a place of business at 111 River Street, 10th
floor, Hoboken, NJ 07030 ("Consultant").

      WHEREAS, Consultant and Company desire to enter into an agreement for the
performance by Consultant of certain consulting services (the "Services"); and

      WHEREAS, Consultant has the specific knowledge, experience, and expertise
to perform the Services;

      NOW, THEREFORE, in consideration of the mutual covenants, terms, and
conditions hereinafter set forth, and intending to be legally bound, Company and
Consultant agree as follows:

1.    SERVICES AND COMPENSATION

      1.1 Services: Consultant shall provide the Services and perform the duties
set in Schedule A. The parties may agree at any time to modify Schedule A.
Company agrees that Consultant shall have reasonable access to Company's
representatives as necessary to perform the Services provided for by this
Agreement. Consultant shall report directly to the CEO of the Company.

      1.2 Compensation. Consultant shall be paid for performance of the Services
as specified in Schedule B.

      1.3 Non-Exclusive Arrangement. Consultant may from time to time act as a
consultant to, perform services for, or enter into agreements similar to this
Agreement with, other persons or entities without the necessity of obtaining
approval from Company; provided, however, that in no event shall Consultant
provide such other persons or entities with, or incorporate into or provide as
part of any services for such other persons or entities, any information or
know-how obtained by Consultant through its conduct of the Services (including,
without limitation, any Confidential Information (as defined below)).

      1.4 Non Competition: Consultant shall not for two years following the
termination or non renewal of this agreement for any reason: (a) directly or
indirectly compete with the Company, or advise or become a partner, consultant,
agent, director, advisor or a 1% shareholder in a business that is substantially
similar to or competitive with the business or planned business of the Company.
Consultant acknowledges and agrees that the geographic, length of term, and
types of activity restrictions contained in this Section 1.4 are reasonable and
necessary to protect the legitimate business interests of the Company.

2.    CONFIDENTIAL INFORMATION

      2.1 Confidentiality. Consultant agrees to maintain in strict confidence
all Confidential Information (as defined below) provided to, or learned or
developed by, Consultant for a period of five (5) years from the date of
termination. Consultant shall not disclose or disseminate any Confidential
Information to any person or entity, except with the prior written consent of
Company. In addition, Consultant shall not use or copy any Confidential
Information for any purpose other than in connection with performance of the
Services hereunder.

      2.2 Definition of Confidential Information. The term "Confidential
Information" shall mean all trade secrets, processes, formulae, data and
know-how, improvements, inventions, chemical or biological materials,
techniques, marketing plans, strategies, customer lists, or other information
that has been created, discovered, or developed by Company, or has otherwise

                                       1

<PAGE>

become known to Company, or which proper rights have been assigned to Company,
as well as any other information and materials that are deemed confidential or
proprietary to or by Company (including, without limitation, all information and
materials of Company's customers and any other third party and their
consultants), regardless of whether any of the foregoing are marked
"confidential" or "proprietary" or communicated to Consultant by Company in
oral, written, graphic or electronic form.

      2.3 Exceptions to Confidential Information. Notwithstanding the foregoing
paragraph, "Confidential Information" shall not include any information or
materials that: (a) are or become known to the general public through no act or
omission of Consultant or any other person with an obligation of confidentiality
to Company, or (b) are required to be disclosed pursuant to applicable law
(provided, however, that prior to any disclosure of Confidential Information as
required by applicable law, Consultant shall advise Company of such required
disclosure promptly upon learning thereof and shall cooperate with Company in
order to afford them a reasonable opportunity to contest or limit such
disclosure).

      2.4 Consultant-Restricted Information. Consultant agrees that Consultant
will not improperly use or disclose to the Company any proprietary or
confidential information or trade secrets of any person or entity with whom
Consultant has an agreement or duty to keep such information or secrets
confidential.

      2.5 Use of Third Party Information. Consultant will not use any equipment,
supplies, chemicals, molecules, organisms, biological materials, or other
physical property, facilities or trade secret information of any present or
former employee or consulting client which are not generally available to the
public, unless Consultant has obtained prior written authorization for such use
and have delivered a copy of such authorization to Company prior to such use.
Notwithstanding such authorization, Company shall have the right, at its sole
discretion, to exclude the use of any of the foregoing by Consultant.

3.    INTELLECTUAL PROPERTY

      3.1 Assignment of Inventions. Consultant agrees that Consultant will
promptly make full written disclosure to Company, will hold in trust for the
sole right and benefit of Company, and hereby assigns, transfers and conveys to
Company, or its designee, all of Consultant's worldwide right, title, and
interest in and to any and all inventions, original works of authorship,
findings, conclusions, data, discoveries, developments, concepts, improvements,
trade secrets, techniques, processes and know-how, whether or not patentable or
registrable under copyright or similar laws, which Consultant may solely or
jointly conceive or develop or reduce to practice, or cause to be conceived or
developed or reduced to practice, in the performance of the Services or which
result, to any extent, from use of Company's premises or property (collectively,
the "Inventions"), including, without limitation, any and all intellectual
property rights inherent in the Inventions and appurtenant thereto including,
without limitation, all patent rights, copyrights, trademarks, know-how and
trade secrets (collectively, "Intellectual Property Rights"). Consultant
acknowledges and agrees that certain of the Inventions (whether made solely by
Consultant or jointly with others) may be "works made for hire," as that term is
defined in the United States Copyright Act, and therefore Company would be
deemed the owner of such Inventions. For purposes of clarification, to the
extent any Invention is not a "work made for hire," such Invention would be
subject to the assignment in the first sentence of this Section 3.1.

      3.2 Further Assurances. Upon the request and at the expense of Company,
Consultant shall execute and deliver any and all instruments and documents and
take such other acts as may be necessary or desirable to document the assignment
and transfer described in Section 3.1 or to enable Company to secure its rights
in the Inventions and any patents, trademarks, copyrights or other intellectual
property rights relating thereto in any and all jurisdictions, or to apply for,
prosecute and enforce patents, trademark registrations, copyrights or other
intellectual property rights in any and all jurisdictions with respect to any
Inventions, or to obtain any extension, validation, re-issue, continuance or
renewal of any such intellectual property right.

                                       2

<PAGE>

4.    REPRESENTATIONS AND WARRANTIES

      4.1 Each party represents and warrants that, to the best of its knowledge,
it has the right to enter into and to perform its obligations hereunder without
thereby breaching any of its obligations to third parties.

      4.2 Consultant represents and warrants to Company that: (i) the Services
performed by Consultant hereunder will be of professional quality, consistent
with generally-accepted industry standards and expectations for work of a
similar nature, (ii) all Services provided to Company hereunder shall conform to
the agreed-upon specifications therefor, if any, (iii) Consultant's performance
under this Agreement and Consultant's retention as a consultant by Company does
not and will not breach any obligation or agreement by which Consultant is bound
to keep in confidence any information Consultant may acquire, or not to compete
with any other person or entity.

5.    TERM

      5.1 Term. The initial term of this Agreement shall begin on January 1.
2005 and shall end on September 30, 2005 ("Initial Term"). Thereafter, the Term
shall be automatically extended by -6-month periods unless Company notifies
Consultant no later than 60 days prior to the end of the Initial Term or any
extension thereof of its intent not to extend the Agreement.

      5.2 Termination. Consultant may terminate this Agreement for any reason
during the term hereof upon thirty (30) days prior written notice to the
Company. Company may terminate the Agreement upon sixty (60) days prior written
notice to the Consultant provided that upon such early termination Company shall
continue to pay Consultant the full consulting fee, benefits and expenses for
the lesser of: (a) 3 months following the termination date, or (b) the end of
the Term (as extended).

      5.3 Return of Company Property. All property belonging to Company in
Consultant's possession or control, including, without limitation, all
Confidential Information (as well as all copies, summaries, or other
representations thereof) and all originals and copies of any documents, devices,
records, data, notes, reports, proposals, lists, correspondence, specifications,
drawings, blueprints, sketches, materials, and equipment shall be and remain the
sole property of Company and shall be returned promptly to Company upon the
expiration non renewal or termination of this Agreement, and earlier if
requested by Company at any time.

      5.4 Survival. In the event this Agreement expires or is terminated for any
reason, the rights and obligations of Sections 5.2, 5.3 and Articles 2, 3, 4, 6
and 7 shall survive such expiration or termination.

6.    NON-SOLICITATION

Non-solicitation. Consultant agrees that during the term of this Agreement and
for one year thereafter, Consultant shall not for any reason, either directly or
indirectly, on Consultant's own behalf or in the service or on behalf of others,
(i) solicit, recruit or attempt to persuade any person to terminate employment
or a consulting relationship with Company or (ii) interfere in any manner with
Company's relationship with, any of Company's co-venturers, vendors, suppliers,
licensors or partners.

7.    MISCELLANEOUS

      7.1 Independent Contractor. For purposes of this Agreement and all
Services to be provided hereunder, Consultant shall not be considered a partner,
co-venturer, agent, employee or representative of Company, but shall remain in
all respects an independent contractor.

      7.2 Rules and Policies. While at Company's facilities, Consultant shall
observe and follow Company's work rules, policies, and standards as the same are

                                       3

<PAGE>

communicated to Consultant from time to time, including, without limitation,
those rules, policies and standards of Company relating to security of and
access to facilities, telephone systems, electronic mail systems, and computer
systems.

      7.3 Successors. All of the terms and provisions of this Agreement shall be
binding upon and inure to the benefit of and be enforceable by the respective
heirs, executors, administrators, legal representatives, successors and assigns
of the parties hereto, except that the duties and responsibilities of Consultant
hereunder are of a personal nature and shall not be assignable or delegable in
whole or in part by Consultant.

      7.4 Amendments. No change, modification, extension, termination or waiver
of this Agreement, or any of the provisions herein contained, shall be valid
unless made in writing and signed by Consultant and a duly authorized
representative of Company.

      7.5 No Waiver. No term or provision of this Agreement will be considered
waived and no breach consented to by either party unless such waiver or consent
is in writing signed on behalf of the party against whom it is asserted. No
consent to or waiver of a breach of this Agreement by either party, whether
express or implied, will constitute a consent to, waiver of, or excuse for any
other, different, or subsequent breach of this Agreement by such party.

      7.6 Severability. Any provisions of this Agreement which are determined to
be invalid or unenforceable in any jurisdiction shall be ineffective to the
extent of such invalidity or unenforceability in such jurisdiction, without
rendering invalid or unenforceable the remaining provisions of this Agreement or
affecting the validity or enforceability of such provisions in any other
jurisdiction. If a court of competent jurisdiction declares any provision of
this Agreement to be invalid or unenforceable, the parties hereto shall request
that such court reduce the scope, duration, or area of the provision, delete
specific words or phrases from the provision, or to replace the provision with a
provision that is valid and enforceable and that comes closest to expressing the
original intention of the parties hereto, and this Agreement shall be
enforceable as so modified in the jurisdiction in which the provision was
declared invalid or unenforceable.

      7.7 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of New Jersey without regard to its conflict of law
provisions.

      7.8 Entire Agreement. This Agreement represents the entire agreement
between the parties regarding the Services provided during the term of this
Agreement and shall supersede all previous communications, representations,
understandings, and agreements, whether oral or written, by or between the
parties with respect thereto, whether theretofore or hereafter disclosed to
Consultant. Without limitation, this Agreement does not supersede any
confidentiality agreement that may have been signed between Company and
Consultant.

      7.9 Counterparts. This Agreement may be executed in two counterparts, each
of which shall be deemed to be an original as against any party whose signature
appears thereon, but both of which together shall constitute but one and the
same instrument.

                      [SIGNATURE PAGE IMMEDIATELY FOLLOWS]

<PAGE>

IN WITNESS HEREOF, the parties have read and agree to be bound by the above
terms and conditions and have entered into this Agreement effective as of the
date set forth above.

Company                                  Consultant
By: /s/ J. Todd Derbin                   By: /s/ Roni Appel
----------------------------------       ---------------------------------------
(Signature)                              (Signature)

J. Todd Derbin                           Roni Appel
----------------------------------       ---------------------------------------
Printed Name                             Printed Name

CEO                                      Manager
----------------------------------       ---------------------------------------
Title                                    Title

19/January 2005
----------------------------------       ---------------------------------------
Date                                     Date

                                   SCHEDULE A

                                   Schedule A

                               CONSULTING SERVICES

For a Total time commitment of 20 hours per week on average, Consultant shall
provide the following services:

      i.    Assisting and advising Company on defining its scientific and
            business milestones;

      ii.   Reviewing and preparing Company technical and business data and
            materials;

      iii.  Assisting the company in preparing its financial statements and
            reports;

      iv.   Assisting the Company in complying with SEC regulation;

      v.    Reviewing and negotiating legal documents and agreements on behalf
            of Company;

      vi.   Assisting in implementing the Company's commercialization strategy.

      vii.  Providing various financial services to Company.

      viii. Other services as agreed from time to time.

      ix.   Roni Appel shall serve as Acting CFO of the Company and sign off on
            various financial statement and representations.

                                   Schedule B

                       COMPENSATION AND PAYMENT SCHEDULE.

      i.    Cash: $7,000 per month payment, starting as of January 1, 2004,
            during the Term of the Agreement.

      ii.   Bonus: Consultant shall receive a payment at year-end equal to 40%
            of the bonus earned by the CEO of the Company. If Consultant
            terminated this Agreement prior to the end of the Term, the bonus
            shall be paid the bonus on a pro rata basis based on the actual
            number of months this Agreement was in effect.

                                       5

<PAGE>

      iii.  Additional one time payment: Upon the execution of this agreement
            Company shall pay Consultant a one-time payment of $4,500.

      iv.   Benefits: Company shall reimburse Consultant for individual health
            insurance expenses.

      v.    Expenses: Company shall reimburse all approved expenses incurred by
            Consultant in connection with the Services provided herein. Expenses
            in excess of $1,000.00 shall have prior authorization from the CEO.

      vi.   Equity: Company shall pay Consultant $1004.5 per month payable in
            3500 unrestricted common shares of Company priced at $0.287 per
            share.

      vii.  Vacation: 21 days not including holidays.

                                       6Exhibit 10.10

                        Government Funding Fee Agreement

This Agreement ("Agreement") is made and entered into as of the 5 day of April,
2004 between David Carpi (the "Finder") and Advaxis, Inc. (the "Company").

      1.    Background: Finder believes he may be able to arrange for Company
            government funded clinical studies for LM LLO E7 or other Advaxis
            products so as to minimize Advaxis' cash burn rate in demonstrating
            the potential of the Listeria system with LM LLO E7 or other Advaxis
            products in human phase I clinical trials and in clinical trials of
            cervical cancer or other cancers. The parties have agreed that
            Finder will attempt to assist Company in obtaining such government
            funding ("Government Clinical Trial Sponsorship") for Clinical
            Trials to be conducted for the Company (such clinical trials testing
            Company products or constructs and sponsored by government through
            the efforts of Finder: " Government Sponsored Clinical Trial").

      2.    Equity Compensation: If Finder successfully arranges Government
            Sponsored Clinical Trial, Company shall grant Finder a non qualified
            common stock option grant with that number of common stock option
            equal to (a) 4% (four percent) of the Economic Value of the
            Government Clinical Trial Sponsorship divided by (b) $100. The
            options are exercisable at $100 per share. For purpose of this
            agreement, "Economic Value" of Government Clinical Trial Sponsorship
            will be determined according to a formula specified in Exhibit A.
            The grant will be made upon final formal approval of the Government
            Clinical Trial Sponsorship. The terms of Company's option plan for
            outside consultants shall apply, however once the options are
            granted, the Consultant will have no requirement to exercise the
            options if the Consulting arrangement is terminated and the
            Consultant will be free to exercise these options at his discretion
            regardless of any ongoing relationship with Advaxis. For example: if
            Finder arranges Government Clinical Trial Sponsorship for a Phase II
            study, with 50 patients with outpatient settings, the Economic Value
            per Exhibit A shall be $1,100,000. In that case, Finder shall
            receive 440 options exercisable at $100 per share. On a post 100:1
            split basis this will be 44,000 options at $1.00 per share.

      3.    Exclusion of other transactions: It is hereby agreed and understood
            that this agreement covers only Government Clinical Trial
            Sponsorship obtained directly through the efforts of Finder and will
            not entitle Finder to receive any fees in connection with any other
            funding or transactions including but not limited to : (a) equity or
            debt financing of any type, (b) NIH grants obtained by or applied
            for by Company directly or with its partners, (c) joint ventures,
            licensing, vendor financing, (d) mergers, acquisition, sale of
            assets (e) clinical studies conducted by Approved Investors and
            funded by Company, or (f) sale of securities of any kind by Company
            (g) government manufacturing process development and pre clinical
            and toxicology support under the NIH and/or RAID program.

      4.    Term: This agreement will expire on April 5, 2005 and thereafter
            will renew on a month-to-month basis unless cancelled in writing by
            either party. Upon termination or non-renewal of this agreement
            Consultant will maintain a list of Investigators that will be
            approached to conduct these trials, provided however that such
            Investigators are pre

<PAGE>

            approved by Company in writing, in advance. Exhibit B, as amended
            from time to time, in writing, contains the list of Company approved
            Investigators ("Approved Investigators").

      5.    Post termination government sponsored clinical studies: If any such
            Approved Investigator agrees to conduct government sponsored
            clinical studies with an Advaxis product within six months of
            termination of this Agreement, and such Government Clinical Trial
            Sponsorship is obtained by Company, then Finder shall be entitled to
            full compensation as set out in section 2 upon the final written
            approval of Government Clinical Trial Sponsorship.

      6.    Subsequent clinical trial sponsorship: If consultant is successful
            in arranging a phase I Government Clinical Trial Sponsorship as
            specified in this agreement, then subsequent Government Sponsored
            Clinical Trials with the same Approved Investigators testing the
            same product or construct will be subject to the terms of this
            agreement provided that: (a) such subsequent Government Sponsored
            Clinical Trial is approved by the government and initiated within 12
            months of the completion of any previous clinical trial covered
            under this agreement, and (b) such subsequent Government Clinical
            Trial Sponsorship is obtained directly through current or previous
            efforts of Finder. For the purpose of clarity, this paragraph is
            designed to enable the Finder to receive fair compensation for
            obtaining Government Sponsored Clinical Trial for phase I trials and
            subsequent trials should the phase I trials be completed
            successfully and subsequent phase I, II, and III trials proceed in a
            natural progression as a result of the Finders work in establishing
            initial government funding for the initial phase I program.

      7.    Entire agreement; dispute: This Agreement constitutes the entire
            agreement between the parties with respect to the subject matter
            hereof. This Agreement may not be amended, modified or waived,
            except in writing signed by both parties. This Agreement may be
            executed in counterparts. Should a dispute arise between the parties
            under or relating to this Agreement, each party agrees that prior to
            initiating any formal proceeding against the other (except when
            injunctive relief is appropriate), the parties will each designate a
            representative for purposes of resolving the dispute. If the
            parties' representatives are unable to resolve the dispute within
            ten business days, the dispute shall be settled by mediation and
            then, if necessary, by arbitration under the then-current commercial
            arbitration rules of the American Arbitration Association. The
            location of the proceeding shall be Princeton, NJ. Judgment upon any
            award rendered by the arbitrator may be entered by any State or
            Federal court having jurisdiction thereof.

      8.    Assignment. This Agreement may not be assigned by any party without
            written consent

      9.    Non Exclusive. The Company may from time to time: (i) engage other
            persons and entities to act as consultants to the Company and
            perform services for the Company, including services that are
            similar to the ones described herein; and (ii) enter into agreements
            similar to this Agreement with other persons or entities, in all
            cases without the necessity of obtaining approval from Consultant.

            IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be

<PAGE>

duly executed on the day of the year first above written.

ADVAXIS, INC.                            FINDER

By: /s/ J. Todd Derbin                   By: /s/ David Carpi
   -------------------------------          -------------------------------
Name:                                    Name:
Title:

<PAGE>

                                    Exhibit A
               Economic Value of Government Sponsored Clinical Trials

Phase I

Fixed costs

Biostatistic Analyses             $300,000
Pharmacokinetic Analyses          $150,000

Variable costs
Cost per patient if outpatient    $ 10,000
Cost per patient if inpatient
or extended stay/observation      $ 14,000

Total cost 450,000 plus number of enrolled patients X 10,000 or 14,000 dependent
on type of study.

Phase II trials (about 30 to 50 patients)

Fixed costs

Biostatistic Analyses             $400,000
Pharmacokinetic Analyses          $200,000

Variable costs
Cost per patient if outpatient    $ 10,000
Cost per patient if inpatient
or extended stay/observation      $ 14,000

Total cost 600,000 plus number of enrolled patients X 10,000 or 14,000 dependent
on type of study.

Phase III trials (about 300-400 patients)

Fixed costs

Biostatistic Analyses             $700,000
Pharmacokinetic Analyses          $400,000

Variable costs
Cost per patient if outpatient    $ 10,000
Cost per patient if inpatient
or extended stay/observation      $ 14,000

<PAGE>

Total cost 1,100,000 plus number of enrolled patients times $10,000 or $14,000
dependent on type of study.

                                    Exhibit B

                             Approved Investigators

JEFFERY WEBER
UNIVERSITY OF SOUTHERN CALIFORNIA

CORNELIA TRIMBLE
JOHNS HOPKINS UNIVERSITY

PHILIP DISAIA
NCI

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]